Monte Rosa Therapeutics

Monte Rosa Therapeutics entered an exclusive agreement with Novartis for VAV1 MGDs, including MRT-6160, with Novartis paying $150 million upfront and potential $2.1 billion in milestones and royalties. MRT-6160, an orally bioavailable VAV1 degrader, is in Phase 1 for immune-mediated conditions, with Novartis leading Phase 2 and beyond. Monte Rosa retains U.S. co-funding and profit-loss sharing rights.

Monte Rosa Therapeutics announced a global agreement with Novartis for the development and commercialization of its VAV1 molecular glue degrader MRT-6160, receiving an upfront payment of $150 million and potential milestone payments up to $2.1 billion. MRT-6160, currently in Phase I for immune-mediated conditions, is described as a potent, selective, and orally bioavailable degrader of VAV1, showing promising activity in preclinical models.

Monte Rosa Therapeutics entered a $2.1 billion global exclusive development and commercialization license agreement with Novartis for VAV1 MGDs, including Phase I drug candidate MRT-6160, aimed at immune-mediated conditions. Novartis will pay $150 million upfront and be responsible for clinical development and commercialization, while Monte Rosa will complete the ongoing Phase I study and co-fund Phase III development. MRT-6160, a VAV1 degrader, showed deep degradation and promising activity in preclinical models of immune-mediated conditions.

Novartis collaborates with Monte Rosa Therapeutics to develop T and B cell-modulating molecular glue degraders targeting VAV1, starting with MRT-6160 for autoimmune diseases, potentially generating over $2.1 billion for Monte Rosa. The collaboration leverages Monte Rosa’s QuEEN platform, combining AI-guided chemistry and proteomics for target discovery. Novartis gains exclusive rights to MRT-6160 and other VAV1 degraders, paying $150 million upfront and up to $2.1 billion in milestones and royalties.

Novartis pays $150M to Monte Rosa for molecular glue degraders targeting VAV1, potentially yielding $2.1B more. MRT-6160, in Phase 1, aims to treat autoimmune diseases. Novartis takes over Phase 2+ development, sharing Phase 3 costs and profits. Monte Rosa plans to extend its research with the funds.

The Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027 report highlights the transformative potential of PROTACs, which selectively degrade disease-implicated proteins. Expected first approval by 2027, with Vepdegestrant (Arvinas) leading in phase 3 trials for ER+/HER2- breast cancer. PROTACs also extend to autoimmune and inflammatory disorders, with strategic collaborations accelerating development. The market is poised for significant growth, driven by advancements and investments in drug development.

The article covers key drug discovery patents from August 2023 to November 2024, highlighting innovations like Amgen’s 15-PGDH inhibitors, brain-penetrant CD38 inhibitors, and next-generation CRM1 inhibitors. It also mentions PIP4K2C inhibitors, POLRMT inhibitors, and MAPT pre-mRNA splicing modulators for cancer and tauopathy treatments. The Drug Hunter team curated over 200 significant patents monthly, providing detailed annotations for each to streamline the review process.